BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Pharmaceutical

Clinical Trials

Oncology

Royalty Purchase Agreement

More Like This

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines

BeOne Medicines' biologics manufacturing facility and clinical R&D center in Hopewell, NJ.

BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology

BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day

BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference

BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026

BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference